A [-2] pro PSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases

Prostate

Volumn 69, Issue 2, 2009, Pages 198-207

  Stephan, Carsten ^a   Kahrs, Anna Maria ^a   Cammann, Henning ^a   Lein, Michael ^a,b   Schrader, Mark ^a   Deger, Serdar ^a   Miller, Kurt ^a   Jung, Klaus ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Berlin Institute for Urologic Research   (Germany)

Author keywords

ANN; Prostate cancer; PSA

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; ARTIFICIAL NEURAL NETWORK; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; GLEASON SCORE; HUMAN; IMMUNOASSAY; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NANOELECTROMECHANICAL SYSTEM; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE TUMOR; AGED; AUTOMATION; GERMANY; HISTOLOGY; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROSTATE; PROSTATE HYPERTROPHY; REGRESSION ANALYSIS; SAMPLE SIZE; SENSITIVITY AND SPECIFICITY;

AGED; AUTOMATION; BERLIN; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; NEURAL NETWORKS (COMPUTER); PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC DISEASES; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; SAMPLE SIZE; SENSITIVITY AND SPECIFICITY;

EID: 58849091840     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20872     Document Type: Article

References (43)

1. Stephan C, Jung K, Lein M, Diamandis EP. PSA and other tissue kallikreins for prostate cancer detection. Eur J Cancer 2007; 43(13):1918-1926.
2. Polascik TJ, Oesterling JE, Partin AW. Prostate specific antigen: A decade of discovery-what we have learned and where we are going. J Urol 1999;162(2):293-306.
3. Lilja H, Christensson A, Dahlen U, Matikainen MT, Nilsson O, Pettersson K, Lovgren T. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotryp-sin. Clin Chem 1991;37(9):1618-1625.
4. Stenman UH, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991;51(1):222-226.
5. Jung K, Lein M, Butz H, Stephan C, Loening SA, Keller T. New insights into the diagnostic accuracy of complexed and total prostate specific antigen using discordance analysis characteristics. J Urol 2006;175(4):1275-1280.
6. Mikolajczyk SD, Marks LS, Partin AW, Rittenhouse HG. Free prostate-specific antigen in serum is becoming more complex. Urology 2002;59(6):797-802.
7. Mikolajczyk SD, Grauer LS, Millar LS, Hill TM, Kumar A, Rittenhouse HG, Wolfert RL, Saedi MS. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 1997;50(5):710-714.
8. Mikolajczyk SD, Marker KM, Millar LS, Kumar A, Saedi MS, Payne JK, Evans CL, Gasior CL, Linton HJ, Carpenter P, Rittenhouse HG. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 2001;61(18):6958-6963.
9. Peter J, Unverzagt C, Krogh TN, Vorm O, Hoesel W. Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. Cancer Res 2001;61(3):957-962.
10. Catalona WJ, Bartsch G, Rittenhouse HG, Evans CL, Linton HJ, Amirkhan A, Horninger W, Klocker H, Mikolajczyk SD. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol 2003;170(6 Pt 1):2181-2185.
11. Khan MA, Sokoll LJ, Chan DW, Mangold LA, Mohr P, Mikolajczyk SD, Linton HJ, Evans CL, Rittenhouse HG, Partin AW. Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%. Urology 2004;64(6):1160-1164.
12. Mikolajczyk SD, Catalona WJ, Evans CL, Linton HJ, Millar LS, Marker KM, Katir D, Amirkhan A, Rittenhouse HG. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem 2004;50(6):1017-1025.
13. Sokoll LJ, Chan DW, Mikolajczyk SD, Rittenhouse HG, Evans CL, Linton HJ, Mangold LA, Mohr P, Bartsch G, Klocker H,Horninger W, Partin AW. Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: Preliminary analysis. Urology 2003;61(2):274-276.
14. Khan MA, Partin AW, Rittenhouse HG, Mikolajczyk SD, Sokoll LJ, Chan DW, Veltri RW. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml. J Urol 2003;170(3):723-726.
15. Catalona WJ, Bartsch G, Rittenhouse HG, Evans CL, Linton HJ, Horninger W, Klocker H, Mikolajczyk SD. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol 2004;171(6 Pt 1):2239-2244.
16. Sokoll LJ, Wang Y, Feng Z, Kagan J, Partin AW, Sanda MG, Thompson IM, Chan DW. [-2]proenzyme prostate specific antigen for prostate cancer detection: A national cancer institute early detection research network validation study. J Urol 2008; 180(2):539-543.
17. Stephan C, Cammann H, Meyer HA, Lein M, Jung K. PSA and new biomarkers within multivariate models to improve early detection of prostate cancer. Cancer Lett 2007;249(1):18-29.
18. Meyer A, Jung K, Lein M, Rudolph B, Schnorr D, Loening SA. Factors influencing the ratio of free to total prostate-specific antigen in serum. Int J Cancer 1997;74(6):630-636.
19. Stephan C, Kahrs AM, Klotzek S, Reiche J, Muller C, Lein M, Deger S, Miller K, Jung K. Toward metrological traceability in the determination of prostate-specific antigen (PSA): Calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards. Clin Chem Lab Med 2008;46(5):623-629.
20. Stephan C, Jung K, Soosaipillai A, Yousef GM, Cammann H, Meyer H, Xu C, Diamandis EP. Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection. BJU Int 2005;96(4):521-527.
21. Stephan C, Jung K, Cammann H, Vogel B, Brux B, Kristiansen G, Rudolph B, Hauptmann S, Lein M, Schnorr D, Sinha P, Loening SA. An artificial neural network considerably improves the diagnostic power of percent free prostate-specific antigen in prostate cancer diagnosis: Results of a 5-year investigation. Int J Cancer 2002;99(3):466-473.
22. Stephan C, Cammann H, Semjonow A, Diamandis EP, Wymenga LFA, Lein M, Sinha P, Loening SA, Jung K. Multi-center evaluation of an artificial neural network to increase prostate cancer detection rate and reduce unnecessary biopsies. Clin Chem 2002;48(8):1279-1287.
23. Finne P, Finne R, Auvinen A, Juusela H, Aro J, Maattanen L, Hakama M, Rannikko S, Tammela TL, Stenman U. Predicting the outcome of prostate biopsy in screen-positive men by a multilayer perceptron network. Urology 2000;56(3):418-422.
24. Kairisto V, Poola A. Software for illustrative presentation of basic clinical characteristics of laboratory tests - GraphROC for Windows. Scand J Clin Lab Invest 1995;55 (Suppl 222):43-60.
25. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumour MARKer prognostic studies (REMARK). Eur J Cancer 2005;41(12):1690-1696.
26. Scaramuzzino DA, Schulte K, Mack BN, Soriano TF, Fritsche HA. Five-year stability study of free and total prostate-specific antigen concentrations in serum specimens collected and stored at -70 degrees C or less. Int J Biol Markers 2007;22(3):206-213.
27. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong EN, Parson RE, Gasior GH, Loveland KG, South-wick PC. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA 1998; 279(19):1542-1547.
28. Stephan C, Xu C, Brown DA, Breit SN, Michael A, Nakamura T, Diamandis EP, Meyer H, Cammann H, Jung K. Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network. Prostate 2006;66(6): 651 -659.
29. Stephan C, Meyer HA, Kwiatkowski M, Recker F, Cammann H, Loening SA, Jung K, Lein M. A (-5, -7) ProPSA Based Artificial Neural Network to Detect Prostate Cancer. Eur Urol 2006; 50(5):1014-1020.
30. Stephan C, Meyer HA, Cammann H, Nakamura T, Diamandis EP, Jung K. Improved prostate cancer detection with a human kallikrein 11 and percentage free PSA-based artificial neural network. Biol Chem 2006;387(6):801 -805.
31. Brown DA, Stephan C, Ward RL, Law M, Hunter M, Bauskin AR, Amin J, Jung K, Diamandis EP, Hampton GM, Russell PJ, Giles GG, Breit SN. Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis. Clin Cancer Res 2006; 12(1):89-96.
32. Bangma CH, Wildhagen MF, Yurdakul G, Schroder FH, Blijenberg BG. The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer. BJU Int 2004;93(6):720-724.
33. Lein M, Semjonow A, Graefen M, Kwiatkowski M, Abramjuk C, Stephan C, Haese A, Chun F, Schnorr D, Loening SA, Jung K. A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen. J Urol 2005;174(6):2150-2153.
34. Peyromaure M, Fulla Y, Debre B, Dinh-Xuan AT. Pro PSA: A ''pro cancer'' form of PSA? Med Hypotheses 2005;64(1):92-95.
35. Veltri RW, Chaudhari M, Miller MC, Poole EC, O'Dowd GJ, Partin AW. Comparison of logistic regression and neural net modeling for prediction of prostate cancer pathologic stage. Clin Chem 2002;48(10):1828-1834.
36. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 2004;350(22):2239-2246.
37. Stephan C, Kramer J, Meyer HA, Kristiansen G, Ziemer S, Deger S, Lein M, Loening SA, Jung K. Different prostate-specific antigen assays give different results on the same blood sample: An obstacle to recommending uniform limits for prostate biopsies. BJU Int 2007;99(6):1427-1431.
38. Stephan C, Xu C, Cammann H, Graefen M, Haese A, Huland H, Semjonow A, Diamandis EP, Remzi M, Djavan B, Wildhagen MF, Blijenberg BG, Finne P, Stenman UH, Jung K, Meyer HA. Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2-10 ng/ml in 4,480 men. World J Urol 2007;25(1):95-103.
39. Stephan C, Xu C, Finne P, Cammann H, Meyer HA, Lein M, Jung K, Stenman UH. Comparison of two different artificial neural networks for prostate biopsy indication in two different patient populations. Urology 2007;70(3):596-601.
40. Carlson GD, Calvanese CB, Partin AW. An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: Results on 4298 cases. Urology 1998; 52(3):455-461.
41. Virtanen A, Gomari M, Kranse R, Stenman UH. Estimation of prostate cancer probability by logistic regression: Free and total prostate-specific antigen, digital rectal examination, and heredity are significant variables. Clin Chem 1999;45(7):987-994.
42. Babaian RJ, Fritsche H, Ayala A, Bhadkamkar V, Johnston DA, Naccarato W, Zhang Z. Performance of a neural network in detecting prostate cancer in the prostate-specific antigen reflex range of 2.5 to 4.0 ng/mL. Urology 2000;56(6):1000-1006.
43. Djavan B, Remzi M, Zlotta A, Seitz C, Snow P, Marberger M. Novel artificial neural network for early detection of prostate cancer. J Clin Oncol 2002;20(4):921-929.